These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11481814)

  • 21. The challenges of prostate cancer detection. Interview by Carren Bersch.
    Tomaszewski JE; Zarbo RJ
    MLO Med Lab Obs; 2004 Feb; 36(2):26, 30-1. PubMed ID: 15002150
    [No Abstract]   [Full Text] [Related]  

  • 22. How to use PSA to screen for prostate cancer.
    Little B; Young M
    Int J Clin Pract; 2003; 57(1):40-2. PubMed ID: 12587941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 24. Does the manner in which information about prostate-specific antigen (PSA) testing is presented affect screening rates?
    Lockman AR
    J Fam Pract; 2001 Oct; 50(10):898. PubMed ID: 11674897
    [No Abstract]   [Full Text] [Related]  

  • 25. PSA screening.
    Cohen S; Schiff S; Kelty P
    Med Health R I; 2005 Mar; 88(3):90-1. PubMed ID: 15915782
    [No Abstract]   [Full Text] [Related]  

  • 26. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 27. [PSA based screening for prostatic cancer].
    Johansen TE
    Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate cancer mortality rates compared to urologist population densities and prostate-specific antigen screening levels on a state-by-state basis in the United States of America.
    Colli JL; Amling CL
    Prostate Cancer Prostatic Dis; 2008; 11(3):247-51. PubMed ID: 18268527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prostate-specific membrane antigen and its role in diagnosis of prostate cancer].
    Chekhonin VP; Grigor'ev ME; Zhirkov IuA; Lebedev DV
    Vopr Med Khim; 2002; 48(1):31-43. PubMed ID: 12068496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prostate cancer and prostate specific antigen screening].
    Camici M
    Minerva Med; 2004 Feb; 95(1):25-34. PubMed ID: 15041924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 33. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Anup P
    BJU Int; 2006 May; 97(5):1039-42. PubMed ID: 16643488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 36. Screening for prostate cancer: a response to four letters.
    Lamb D; Delahunt B
    N Z Med J; 2005 Apr; 118(1212):U1390. PubMed ID: 15806187
    [No Abstract]   [Full Text] [Related]  

  • 37. What to do with an abnormal PSA test.
    Loeb S; Catalona WJ
    Oncologist; 2008 Mar; 13(3):299-305. PubMed ID: 18378540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on screening for prostate cancer with prostate-specific antigen.
    Schmid HP; Riesen W; Prikler L
    Crit Rev Oncol Hematol; 2004 Apr; 50(1):71-8. PubMed ID: 15094160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncertainty and quality of life among men undergoing active surveillance for prostate cancer in the United States and Ireland.
    Hegarty JM; Wallace M; Comber H
    Am J Mens Health; 2008 Jun; 2(2):133-42. PubMed ID: 19477777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.